Interpretation of the latest news and market dynamics of Cemiplimab in 2025

As of2025 June, cemiplimab (Cemiplimab, trade name: Libtayo) has not been approved for marketing by the National Medical Products Administration (NMPA) in China, nor has it been included in the medical insurance directory. Therefore, its domestic market access is still in the waiting stage. Currently, cimepilimab is available in the US and European markets and is mainly used for the treatment of advanced or metastatic cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC) and other indications.

In the Chinese market, the price of cimipilimab has not been officially announced. According to pricing information in overseas markets, the specifications of 350mg/7mL (50mg/mL) may be priced between RMB 40,000 and RMB 100,000 per box. The specific price is affected by exchange rates and regional differences. In addition, there are currently no generic versions of cimepilimab on the market. This means that if it is launched in China in the future, patients may face higher drug costs.

From the perspective of market prospects, the potential market value of cimepilimab in China is considerable. According to market research data, it is expected that by 2032, the annual sales in the Chinese market will reach approximately 23.4 billion, with a compound annual growth rate of 14.5%. This growth was primarily driven by increased demand for treatments in indications such as cutaneous squamous cell carcinoma and non-small cell lung cancer.

However, the launch of cimepilimab in the Chinese market still faces certain challenges. First of all, there are a number of PD-1/PD-L1 inhibitors on the market in China, such as sintilimab (Tyvyt), toripalimab (Tuoyi) and camrelizumab (Acreli), etc., and the market competition is fierce. Secondly, the high price of cimepilimab may affect its inclusion in the medical insurance directory. Therefore, to successfully enter the Chinese market, cimepilimab may need to seek differentiated competitive advantages in terms of efficacy, price, or expansion of indications.

To sum up, cimepilimab has not yet been launched in the Chinese market, the price information is unclear, and the market prospect is broad but competition is fierce. Whether it can successfully enter the Chinese market in the future will depend on its performance in terms of efficacy, price, and expansion of indications. While patients are waiting for the drug to be launched, they should pay attention to the treatment options of PD-1/PD-L1 inhibitors available in China.

Reference materials:https://www.libtayohcp.com/